Related Experiment Videos
Mutations and amplification of oncogenes in endometrial cancer
D Niederacher1, H X An, Y J Cho
1Department of Gynecology and Obstetrics, Heinrich-Heine-University, Düsseldorf, Germany. niederac@uni-duesseldorf.de
Abstract:
Alterations in oncogenes are critical steps in the development of endometrial cancer. To investigate the potential clinical relevance of the amplification of the oncogenes c-erbB2, c-myc, and int-2 and the mutation of K-ras in endometrial cancer, 112 tumors were examined using PCR-based fluorescent DNA technology. Amplification of the three oncogenes and the mutation of K-ras were correlated with age, tumor size, lymph node status, metastases, stage, histological types, grade, steroid hormone receptor expression (estrogen receptor, ER; progesterone receptor, PgR), family history of cancer, previous history of cancer or precursor lesions, and previous history of hormone replacement therapy. Oncogene amplification of c-erbB2 was detected in 18.9%, of c-myc in 2.7% and of int-2 in 4.2%, and K-ras mutation in 11.6%. No significant correlations could be detected between amplification of c-erbB2 and any of the other parameters. Mutation of K-ras is associated with positive expression of PgR. This might indicate that mutation and activation of K-ras are involved in the development of hormonal independence in endometrial cancer.
Insights
Alterations in oncogenes like c-erbB2, c-myc, int-2, and K-ras are key in endometrial cancer. K-ras mutations correlate with progesterone receptor expression, suggesting a role in hormonal independence.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogene alterations are crucial in endometrial cancer development.
- Investigating specific oncogenes (c-erbB2, c-myc, int-2, K-ras) provides insight into cancer progression.
Purpose of the Study:
- To determine the clinical relevance of c-erbB2, c-myc, int-2 amplification, and K-ras mutation in endometrial cancer.
- To correlate these genetic alterations with various clinical and pathological parameters.
Main Methods:
- Analysis of 112 endometrial tumors using PCR-based fluorescent DNA technology.
- Correlation analysis with patient age, tumor characteristics, hormone receptor status, and medical history.
Main Results:
- Prevalence: c-erbB2 amplification (18.9%), c-myc amplification (2.7%), int-2 amplification (4.2%), K-ras mutation (11.6%).
- No significant correlation found for c-erbB2 amplification with other parameters.
- K-ras mutation showed a significant association with positive progesterone receptor (PgR) expression.
Conclusions:
- K-ras mutation's association with PgR suggests its potential role in the development of hormonal independence in endometrial cancer.
- Further research is warranted to elucidate the precise mechanisms and clinical implications.